GH Research Prices 6.53M Shares at $18 for $117.5M Gross Proceeds
GH Research PLC priced an underwritten offering of 6,527,779 ordinary shares at $18 each, generating approximately $117.5 million in gross proceeds before expenses. The equity sale, supported by Lynx1 Capital Management, Deep Track Capital and Foresite Capital, is expected to close on April 30, 2026.
1. Offering Terms
GH Research PLC announced the pricing of 6,527,779 ordinary shares at $18.00 per share, raising approximately $117.5 million in gross proceeds before underwriting discounts, commissions and expenses. The offering is set to close on April 30, 2026, subject to customary closing conditions.
2. Institutional Participation
The offering was initiated by Lynx1 Capital Management, with additional participation from Deep Track Capital and Foresite Capital, reflecting strong institutional interest in the company’s clinical-stage pipeline.
3. Underwriting Management
Stifel, Cantor and RBC Capital Markets are acting as joint book-running managers for the equity sale, while Canaccord Genuity and Citizens Capital Markets serve as co-lead managers, overseeing distribution and investor allocations.
4. Company Focus
GH Research PLC is a clinical-stage biopharmaceutical company developing proprietary mebufotenin therapies for treatment-resistant depression, and intends to deploy the new capital to advance its lead depression treatment program through upcoming clinical milestones.